Associations between Constipation and Use of Levodopa with Nutritional Status, Polypharmacy, and Stage of Parkinson's Disease

Nutrients. 2024 Sep 13;16(18):3092. doi: 10.3390/nu16183092.

Abstract

Introduction: Parkinson's disease (PD) is a highly prevalent disease characterized by motor and non-motor symptoms; the latter include constipation, which is considered a prodromal symptom. On the other hand, sarcopenia, polypharmacy, and malnutrition due to deficits are common in PD and lead to poorer health and quality of life.

Objective: to associate constipation and use of levodopa with nutritional status, sarcopenia, duration and stage of the disease, and polypharmacy in individuals with PD.

Materials and methods: analytical cross-sectional observational study where an online survey was applied to 161 people suffering from PD.

Results: a significant association is observed between constipation and BMI (p = 0.022), as well as between the use of levodopa with BMI (p = 0.049) and polypharmacy (p = 0.046). On the other hand, there is a relationship between the average time of PD diagnosis and constipation (p = 0.0047). Finally, there is a relationship between SARC-F score applied to those over 60 years of age (p = 0.0446) and the use of levodopa. Having sarcopenia, being overweight, and having had the disease for less than five years is associated with a higher probability of experiencing constipation, according to the logistic regression analysis (p > 0.005).

Conclusion: nutritional assessment and subsequent follow-up is of vital importance to avoid complications that could be associated with levodopa use, constipation, and sarcopenia.

Keywords: Parkinson’s disease; constipation; levodopa; nutritional status; polypharmacy.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / therapeutic use
  • Body Mass Index
  • Constipation* / chemically induced
  • Constipation* / epidemiology
  • Cross-Sectional Studies
  • Female
  • Humans
  • Levodopa* / adverse effects
  • Levodopa* / therapeutic use
  • Male
  • Middle Aged
  • Nutrition Assessment
  • Nutritional Status*
  • Parkinson Disease* / complications
  • Parkinson Disease* / drug therapy
  • Polypharmacy*
  • Quality of Life
  • Sarcopenia / epidemiology

Substances

  • Levodopa
  • Antiparkinson Agents

Grants and funding

This research received no external funding.